Patents by Inventor Mark Larche
Mark Larche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9850281Abstract: Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.Type: GrantFiled: May 30, 2013Date of Patent: December 26, 2017Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
-
Patent number: 9744222Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: October 17, 2016Date of Patent: August 29, 2017Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche
-
Patent number: 9347937Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: GrantFiled: June 14, 2013Date of Patent: May 24, 2016Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Patent number: 9340580Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerization therapy.Type: GrantFiled: August 15, 2008Date of Patent: May 17, 2016Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Mark Larche
-
Patent number: 9168295Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.Type: GrantFiled: August 22, 2013Date of Patent: October 27, 2015Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
-
Publication number: 20150218215Abstract: Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.Type: ApplicationFiled: May 30, 2013Publication date: August 6, 2015Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
-
Patent number: 9017689Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: February 15, 2011Date of Patent: April 28, 2015Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche, Christopher Hugh Reginald Stocker
-
Publication number: 20150098969Abstract: Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT (Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR (Alt34A; SEQ ID NO: 107) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ (Alt13A; SEQ ID NO: 83) or a T cell epiType: ApplicationFiled: May 30, 2013Publication date: April 9, 2015Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
-
Patent number: 8821887Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerization, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class II-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterized by an inappropriate immune response to the protein allergen from which the second polypeptide derives.Type: GrantFiled: August 14, 2009Date of Patent: September 2, 2014Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Patent number: 8753644Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: February 5, 2010Date of Patent: June 17, 2014Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche, Christopher Hugh Reginald Stocker
-
Patent number: 8652485Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: GrantFiled: August 15, 2008Date of Patent: February 18, 2014Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche
-
Patent number: 8551492Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.Type: GrantFiled: May 30, 2008Date of Patent: October 8, 2013Assignee: Circassia LimitedInventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
-
Publication number: 20130243798Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: ApplicationFiled: February 15, 2011Publication date: September 19, 2013Applicant: CIRCASSIA LIMITEDInventors: Christopher Hugh Reginald Stocker, Paul Laidler, Mark Larche, Roderick Peter Hafner
-
Patent number: 8491910Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: GrantFiled: August 14, 2009Date of Patent: July 23, 2013Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Publication number: 20120148612Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: ApplicationFiled: February 5, 2010Publication date: June 14, 2012Applicant: CIRCASSIA LIMITEDInventors: Roderick Peter Hafner, Paul Laidler, Guy Layton, Christopher Hugh Reginald Stocker, Mark Larche
-
Publication number: 20120108524Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: ApplicationFiled: August 14, 2009Publication date: May 3, 2012Applicant: CIRCASSIA LIMITEDInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Publication number: 20110206709Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class Il-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives.Type: ApplicationFiled: August 14, 2009Publication date: August 25, 2011Applicant: CIRCASSIA LIMITEDInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Publication number: 20110142867Abstract: Methods for desensitising an individual to a selected polypeptide antigen are provided. The methods entail administration of T cell epitope containing peptides from a polypeptide antigen in such a way as to establish a tolergeneic environment, that is, a state of hyporesponsiveness to the peptides. The selected polypeptide antigen is then administered such that the state of hyporesponsiveness and co-administration of the selected antigen are sufficient to desensitise the individual to the polypeptide antigen. Also provided are therapeutic systems useful in the methods of the invention, and the use of polypeptide antigens and peptides in the manufacture of medicaments in the methods of the invention.Type: ApplicationFiled: August 20, 2010Publication date: June 16, 2011Inventors: Mark Larche, Philip William Ledger
-
Publication number: 20100298239Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy.Type: ApplicationFiled: August 15, 2008Publication date: November 25, 2010Applicant: CIRCASSIA LIMITEDInventors: Roderick Peter Hafner, Mark Larche
-
Publication number: 20100260805Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.Type: ApplicationFiled: August 15, 2008Publication date: October 14, 2010Applicant: CIRCASSIA LIMITEDInventors: Roderick Peter Hafner, Paul Laidler, Mark Larche